Journal Article

DKFZ-2024-01644

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png H-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma.

Angelova, A. L. (First author)DKFZ* ; Barf, M.DKFZ* ; Just, A.DKFZ* ; Leuchs, B.DKFZ* ; Rommelaere, J.DKFZ* ; Ungerechts, G. (Last author)DKFZ*

2024
MDPI Basel

This record in other databases:  

Please use a persistent id in citations: doi:10.3390/cancers16152711

Abstract: The rat protoparvovirus H-1 (H-1PV) is an oncolytic virus known for its anticancer properties in laboratory models of various human tumors, including non-Hodgkin lymphomas (NHL) of B-cell origin. However, H-1PV therapeutic potential against hematological malignancies of T-cell origin remains underexplored. The aim of the present study was to conduct a pilot preclinical investigation of H-1PV-mediated oncolytic effects in cutaneous T-cell lymphoma (CTCL), a type of NHL that is urgently calling for innovative therapies. We demonstrated H-1PV productive infection and induction of oncolysis in both classically grown CTCL suspension cultures and in a novel, in vivo-relevant, heterotypic spheroid model, but not in healthy donor controls, including peripheral blood mononuclear cells (PBMCs). H-1PV-mediated oncolysis of CTCL cells was not prevented by Bcl-2 overexpression and was accompanied by increased extracellular ATP release. In CTCL spheroid co-cultures with PBMCs, increased spheroid infiltration with immune cells was detected upon co-culture treatment with the virus. In conclusion, our preclinical data show that H-1PV may hold significant potential as an ingenious viroimmunotherapeutic drug candidate against CTCL.

Keyword(s): cutaneous T-cell lymphoma (CTCL) ; heterotypic CTCL spheroid ; oncolytic H-1 parvovirus ; virotherapy

Note: #EA:D490#LA:D490#

---

Contributing Institute(s):

1. KKE Virotherapie (D490)
2. Virus-assoziierte Karzinogenese (D430)
3. Erimitus im DKFZ (Z999)

Research Program(s):

1. 314 - Immunologie und Krebs (POF4-314) (POF4-314)

Appears in the scientific report 2024

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---